Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Royal Marsden Hospital, Sutton, United Kingdom



Survival: 18.6 months
   
Toxicity Grade: 4
   
Treatments: Chemotherapy
   
Drugs:
Country: United Kingdom
   
City/State/Province: Sutton
   
Hospital: Royal Marsden Hospital
   
Journal: Link
   
Date: 5/2012

Description:
Patients:
This phase 2 study involved 108 metastatic castration-resistant prostate cancer patients with a median age of 71 years.

Treatment:
Patients were treated with the chemotherapy agent eribulin mesylate.

Toxicities:
The most severe toxicities were of grade 4 and included febrile neutropenia and leukopenia. Grade 3 diarrhea and fatigue were also reported.

Results:
The median overall survival was 18.6 months.

Support:
This study was supported by Eisai Inc., makers of eribulin mesylate (brand name: Halaven).

Correspondence: Dr. J. S. de Bono; email: johann.de-bono@icr.ac.uk

E-mail to a Friend Email Physician More Information